Acquired lipodystrophy

Summary

Acquired lipodystrophy (MONDO:0020089) is a disease. A subtype of acquired metabolic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acquired lipodystrophy
Mondo ID	MONDO:0020089
Orphanet	98307
UMLS	C0877192
MedGen	798705
GARD	0012602
MedDRA	10049287
Is cancer (heuristic)	no

Also known as: acquired lipodystrophy (disease)

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › acquired metabolic disease › acquired lipodystrophy

Related subtypes (12): acquired carbohydrate metabolism disease, AL amyloidosis, carotenemia, acquired xanthinuria, acquired mineral metabolism disease, acquired hyperprolactinemia, acquired lactic acidosis, acquired adrenogenital syndrome, paroxysmal nocturnal hemoglobinuria, auto-brewery syndrome, bladder fermentation syndrome, acquired porphyria

Subtypes (2): acquired partial lipodystrophy, acquired generalized lipodystrophy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.